Aardvark Therapeutics AARD
NASDAQ AARD
$5.01 -0.26 (-4.84%)
As of: Oct 2, 2026 · 10:55 AM EDT

Aardvark Therapeutics (AARD) Net Equity Issued and Repurchased (2024 - 2026)

Updated

Aardvark Therapeutics' Net Equity Issued and Repurchased came in at $255,000 for Q2 2026.

Analysis

Aardvark Therapeutics (AARD) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Aardvark Therapeutics reported Net Equity Issued and Repurchased of $259,000, down 99.7% year-over-year; for FY2025, it came in at $91.08 million, up 7.1% from FY2024.

  • Going back by year, Net Equity Issued and Repurchased was $85 million in FY2024.
  • The Q2 2026 figure represents the highest quarterly Net Equity Issued and Repurchased since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 43.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 6.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 9.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 47.70 Mn
10 Aardvark Therapeutics 115.33 Mn 41.43 Mn - 255,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 255,000.00
Mar 31, 2026 4,000.00
Mar 31, 2025 91.08 Mn
Jun 30, 2024 85.00 Mn
API Access

Aardvark Therapeutics Net Equity Issued and Repurchased API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=AARD&period=max&api_key=YOUR_API_KEY